DDInter1822 DDInter1123
Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L
Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid. On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for this indication under the name BRONCHITOL® by Chiesi USA Inc.
Tobramycin {u} (Compound) causes {v} (Side Effect) Discomfort
Discomfort {u} (Side Effect) is caused by {v} (Compound) Mannitol
Tobramycin {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Calcium glucoheptonate
Calcium glucoheptonate {u} (Compound) resembles {v} (Compound) Mannitol
Tobramycin {u} (Compound) resembles {v} (Compound) Paromomycin
Paromomycin {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Mannitol
Tobramycin {u} (Compound) resembles {v} (Compound) Lactulose
Lactulose {u} (Compound) is included by {v} (Pharmacologic Class) Osmotic Activity
Osmotic Activity {u} (Pharmacologic Class) includes {v} (Compound) Mannitol
Tobramycin (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Mannitol (Compound)
Tobramycin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Calcium glucoheptonate (Compound) and Calcium glucoheptonate (Compound) resembles Mannitol (Compound)
Tobramycin (Compound) resembles Paromomycin (Compound) and Paromomycin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Mannitol (Compound)
Tobramycin (Compound) resembles Lactulose (Compound) and Lactulose (Compound) is included by Osmotic Activity (Pharmacologic Class) and Osmotic Activity (Pharmacologic Class) includes Mannitol (Compound)